Long-Term Collaboration Network Based on ClinicalTrials.gov Database in the Pharmaceutical Industry

Increasing costs, risks, and productivity problems in the pharmaceutical industry are important recent issues in the biomedical field. Open innovation is proposed as a solution to these issues. However, little statistical analysis related to collaboration in the pharmaceutical industry has been conducted so far. Meanwhile, not many cases have analyzed the clinical trials database, even though it is the information source with the widest coverage for the pharmaceutical industry. The purpose of this study is to test the clinical trials information as a probe for observing the status of the collaboration network and open innovation in the pharmaceutical industry. This study applied the social network analysis method to clinical trials data from 1980 to 2016 in ClinicalTrials.gov. Data were divided into four time periods—1980s, 1990s, 2000s, and 2010s—and the collaboration network was constructed for each time period. The characteristic of each network was investigated. The types of agencies participating in the clinical trials were classified as a university, national institute, company, or other, and the major players in the collaboration networks were identified. This study showed some phenomena related to the pharmaceutical industry that could provide clues to policymakers about open innovation. If follow-up studies were conducted, the utilization of the clinical trial database could be further expanded, which is expected to help open innovation in the pharmaceutical industry.

[1]  Robert M Califf,et al.  Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. , 2012, JAMA.

[2]  Kay Dickersin,et al.  Registering clinical trials. , 2003, JAMA.

[3]  H. Glass,et al.  ClinicalTrials.gov: An Underutilized Source of Research Data About the Design and Conduct of Commercial Clinical Trials , 2015, Therapeutic innovation & regulatory science.

[4]  Ida Sim,et al.  Sponsorship and design characteristics of trials registered in ClinicalTrials.gov. , 2013, Contemporary clinical trials.

[5]  Anthony J. Sinskey,et al.  Trends in the globalization of clinical trials , 2008, Nature Reviews Drug Discovery.

[6]  Khaled Almgren,et al.  An empirical comparison of influence measurements for social network analysis , 2016, Social Network Analysis and Mining.

[7]  Loet Leydesdorff,et al.  “Open innovation” and “triple helix” models of innovation: can synergy in innovation systems be measured? , 2016, ArXiv.

[8]  Na Zhang,et al.  An evolutionary process of global nanotechnology collaboration: a social network analysis of patents at USPTO , 2017, Scientometrics.

[9]  J. Yun.  How do we conquer the growth limits of capitalism? Schumpeterian Dynamics of Open Innovation , 2015 .

[10]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[11]  W. Powell,et al.  Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology. , 1996 .

[12]  C. Mehta,et al.  The future of drug development: advancing clinical trial design , 2009, Nature Reviews Drug Discovery.

[13]  Hildrun Kretschmer,et al.  Coauthorship networks of invisible colleges and institutionalized communities , 1994, Scientometrics.

[14]  C. Roh,et al.  Medical innovation and social externality , 2017 .

[15]  D. Dougherty.  Taking advantage of emergence for complex innovation eco-systems , 2017 .

[16]  B. Munos.  Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.

[17]  K I Kaitin,et al.  Deconstructing the Drug Development Process: The New Face of Innovation , 2010, Clinical pharmacology and therapeutics.

[18]  R. Simes.  Publication bias: the case for an international registry of clinical trials. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Fritsch,et al.  The impact of network structure on knowledge transfer: an application of social network analysis in the context of regional innovation networks , 2010 .

[20]  Ulrich Witt,et al.  What kind of innovations do we need to secure our future? , 2016 .

[21]  M. Newman.  Coauthorship networks and patterns of scientific collaboration , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Anil K. Gupta,et al.  Connecting corporations and communities: Towards a theory of social inclusive open innovation , 2017 .

[23]  Dar-zen Chen,et al.  The Evolution of Knowledge Spillover and Company cluster in Semiconductor Industry , 2010, PICMET 2010 TECHNOLOGY MANAGEMENT FOR GLOBAL ECONOMIC GROWTH.

[24]  D. DeMets,et al.  A historical perspective on clinical trials innovation and leadership: where have the academics gone? , 2011, JAMA.

[25]  R. W. Hansen,et al.  Journal of Health Economics , 2016 .